U.S. Markets closed

Precipio, Inc. (PRPO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6240-0.0260 (-4.00%)
At close: 04:00PM EDT
0.6700 +0.05 (+7.37%)
After hours: 07:19PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6500
Bid0.6074 x 1200
Ask0.7000 x 900
Day's Range0.6240 - 0.6502
52 Week Range0.4700 - 1.7700
Avg. Volume88,421
Market Cap14.24M
Beta (5Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)-0.8480
Earnings DateApr 03, 2023 - Apr 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • GlobeNewswire

    Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call

    Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ETNEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Pre

  • GlobeNewswire

    Precipio Ships First IV-Cell® Order to Major US Healthcare System

    Products Division revenues begin to diversify beyond HemeScreen®NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system. The healthcare system (unnamed for competitive reasons) has successfully completed the validation of the media and will begin the gradual incorporation into clinical use. About IV-Cel

  • GlobeNewswire

    CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers

    Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growthNEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read "revenues in Q2-2023 are now estimated to be ~50% greater than Q1-2023" rather than "~50% greater than Q1-2022". The corrected release follows: Specialty cancer diagnostics company